The threat of avian influenza A (H5N1). Part IV: development of vaccines
Identifieur interne : 000251 ( Istex/Corpus ); précédent : 000250; suivant : 000252The threat of avian influenza A (H5N1). Part IV: development of vaccines
Auteurs : Jindrich Cinatl Jr ; Martin Michaelis ; Hans W. DoerrSource :
- Medical Microbiology and Immunology [ 0300-8584 ] ; 2007-12-01.
Abstract
Abstract: Among emerging and re-emerging infectious diseases, influenza constitutes one of the major threats to mankind. In this review series epidemiologic, virologic and pathologic concerns raised by infections of humans with avian influenza virus A/H5N1 are discussed. This fourth part focuses on vaccine development. Several phase I clinical studies with vaccines against H5 viruses have demonstrated limited efficacy compared to seasonal influenza vaccines. To induce protective immunity two immunisations with increased amounts of H5N1 vaccine were required. Novel vaccination strategies that are egg- and adjuvant-independent, broadly cross-reactive and long-lasting are highly desirable.
Url:
DOI: 10.1007/s00430-007-0052-3
Links to Exploration step
ISTEX:6A375247B03FB33CBC942FE9C9E5976035C9F2EFLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The threat of avian influenza A (H5N1). Part IV: development of vaccines</title><author><name sortKey="Cinatl Jr, Jindrich" sort="Cinatl Jr, Jindrich" uniqKey="Cinatl Jr J" first="Jindrich" last="Cinatl Jr">Jindrich Cinatl Jr</name><affiliation><mods:affiliation>Institute for Medical Virology, Hospital of the Johann Wolfgang Goethe University, Paul-Ehrlich-Str. 40, 60596, Frankfurt/M, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: cinatl@em.uni-frankfurt.de</mods:affiliation></affiliation></author><author><name sortKey="Michaelis, Martin" sort="Michaelis, Martin" uniqKey="Michaelis M" first="Martin" last="Michaelis">Martin Michaelis</name><affiliation><mods:affiliation>Institute for Medical Virology, Hospital of the Johann Wolfgang Goethe University, Paul-Ehrlich-Str. 40, 60596, Frankfurt/M, Germany</mods:affiliation></affiliation></author><author><name sortKey="Doerr, Hans W" sort="Doerr, Hans W" uniqKey="Doerr H" first="Hans W." last="Doerr">Hans W. Doerr</name><affiliation><mods:affiliation>Institute for Medical Virology, Hospital of the Johann Wolfgang Goethe University, Paul-Ehrlich-Str. 40, 60596, Frankfurt/M, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: h.w.doerr@em.uni-frankfurt.de</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6A375247B03FB33CBC942FE9C9E5976035C9F2EF</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1007/s00430-007-0052-3</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-N26CZ5CC-J/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000251</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000251</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The threat of avian influenza A (H5N1). Part IV: development of vaccines</title><author><name sortKey="Cinatl Jr, Jindrich" sort="Cinatl Jr, Jindrich" uniqKey="Cinatl Jr J" first="Jindrich" last="Cinatl Jr">Jindrich Cinatl Jr</name><affiliation><mods:affiliation>Institute for Medical Virology, Hospital of the Johann Wolfgang Goethe University, Paul-Ehrlich-Str. 40, 60596, Frankfurt/M, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: cinatl@em.uni-frankfurt.de</mods:affiliation></affiliation></author><author><name sortKey="Michaelis, Martin" sort="Michaelis, Martin" uniqKey="Michaelis M" first="Martin" last="Michaelis">Martin Michaelis</name><affiliation><mods:affiliation>Institute for Medical Virology, Hospital of the Johann Wolfgang Goethe University, Paul-Ehrlich-Str. 40, 60596, Frankfurt/M, Germany</mods:affiliation></affiliation></author><author><name sortKey="Doerr, Hans W" sort="Doerr, Hans W" uniqKey="Doerr H" first="Hans W." last="Doerr">Hans W. Doerr</name><affiliation><mods:affiliation>Institute for Medical Virology, Hospital of the Johann Wolfgang Goethe University, Paul-Ehrlich-Str. 40, 60596, Frankfurt/M, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: h.w.doerr@em.uni-frankfurt.de</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Medical Microbiology and Immunology</title><title level="j" type="abbrev">Med Microbiol Immunol</title><idno type="ISSN">0300-8584</idno><idno type="eISSN">1432-1831</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="2007-12-01">2007-12-01</date><biblScope unit="volume">196</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="213">213</biblScope><biblScope unit="page" to="225">225</biblScope></imprint><idno type="ISSN">0300-8584</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0300-8584</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Among emerging and re-emerging infectious diseases, influenza constitutes one of the major threats to mankind. In this review series epidemiologic, virologic and pathologic concerns raised by infections of humans with avian influenza virus A/H5N1 are discussed. This fourth part focuses on vaccine development. Several phase I clinical studies with vaccines against H5 viruses have demonstrated limited efficacy compared to seasonal influenza vaccines. To induce protective immunity two immunisations with increased amounts of H5N1 vaccine were required. Novel vaccination strategies that are egg- and adjuvant-independent, broadly cross-reactive and long-lasting are highly desirable.</div></front></TEI><istex><corpusName>springer-journals</corpusName><author><json:item><name>Jindrich Cinatl jr</name><affiliations><json:string>Institute for Medical Virology, Hospital of the Johann Wolfgang Goethe University, Paul-Ehrlich-Str. 40, 60596, Frankfurt/M, Germany</json:string><json:string>E-mail: cinatl@em.uni-frankfurt.de</json:string></affiliations></json:item><json:item><name>Martin Michaelis</name><affiliations><json:string>Institute for Medical Virology, Hospital of the Johann Wolfgang Goethe University, Paul-Ehrlich-Str. 40, 60596, Frankfurt/M, Germany</json:string></affiliations></json:item><json:item><name>Hans W. Doerr</name><affiliations><json:string>Institute for Medical Virology, Hospital of the Johann Wolfgang Goethe University, Paul-Ehrlich-Str. 40, 60596, Frankfurt/M, Germany</json:string><json:string>E-mail: h.w.doerr@em.uni-frankfurt.de</json:string></affiliations></json:item></author><articleId><json:string>52</json:string><json:string>s00430-007-0052-3</json:string></articleId><arkIstex>ark:/67375/VQC-N26CZ5CC-J</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>ReviewPaper</json:string></originalGenre><abstract>Abstract: Among emerging and re-emerging infectious diseases, influenza constitutes one of the major threats to mankind. In this review series epidemiologic, virologic and pathologic concerns raised by infections of humans with avian influenza virus A/H5N1 are discussed. This fourth part focuses on vaccine development. Several phase I clinical studies with vaccines against H5 viruses have demonstrated limited efficacy compared to seasonal influenza vaccines. To induce protective immunity two immunisations with increased amounts of H5N1 vaccine were required. Novel vaccination strategies that are egg- and adjuvant-independent, broadly cross-reactive and long-lasting are highly desirable.</abstract><qualityIndicators><score>8.104</score><pdfWordCount>9220</pdfWordCount><pdfCharCount>59943</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>13</pdfPageCount><pdfPageSize>595 x 791 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>92</abstractWordCount><abstractCharCount>695</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>The threat of avian influenza A (H5N1). Part IV: development of vaccines</title><genre><json:string>review-article</json:string></genre><host><title>Medical Microbiology and Immunology</title><language><json:string>unknown</json:string></language><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><issn><json:string>0300-8584</json:string></issn><eissn><json:string>1432-1831</json:string></eissn><journalId><json:string>430</json:string></journalId><volume>196</volume><issue>4</issue><pages><first>213</first><last>225</last></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Immunology</value></json:item><json:item><value>Medical Microbiology</value></json:item></subject></host><ark><json:string>ark:/67375/VQC-N26CZ5CC-J</json:string></ark><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1007/s00430-007-0052-3</json:string></doi><id>6A375247B03FB33CBC942FE9C9E5976035C9F2EF</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-N26CZ5CC-J/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-N26CZ5CC-J/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/VQC-N26CZ5CC-J/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">The threat of avian influenza A (H5N1). Part IV: development of vaccines</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><availability><licence><p>Springer-Verlag, 2007</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</p></availability><date>2007-05-03</date></publicationStmt><notesStmt><note type="review-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note>Review</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">The threat of avian influenza A (H5N1). Part IV: development of vaccines</title><author xml:id="author-0000" corresp="yes"><persName><forename type="first">Jindrich</forename><surname>Cinatl jr</surname></persName><email>cinatl@em.uni-frankfurt.de</email><affiliation>Institute for Medical Virology, Hospital of the Johann Wolfgang Goethe University, Paul-Ehrlich-Str. 40, 60596, Frankfurt/M, Germany</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Martin</forename><surname>Michaelis</surname></persName><affiliation>Institute for Medical Virology, Hospital of the Johann Wolfgang Goethe University, Paul-Ehrlich-Str. 40, 60596, Frankfurt/M, Germany</affiliation></author><author xml:id="author-0002" corresp="yes"><persName><forename type="first">Hans</forename><surname>Doerr</surname></persName><email>h.w.doerr@em.uni-frankfurt.de</email><affiliation>Institute for Medical Virology, Hospital of the Johann Wolfgang Goethe University, Paul-Ehrlich-Str. 40, 60596, Frankfurt/M, Germany</affiliation></author><idno type="istex">6A375247B03FB33CBC942FE9C9E5976035C9F2EF</idno><idno type="ark">ark:/67375/VQC-N26CZ5CC-J</idno><idno type="DOI">10.1007/s00430-007-0052-3</idno><idno type="article-id">52</idno><idno type="article-id">s00430-007-0052-3</idno></analytic><monogr><title level="j">Medical Microbiology and Immunology</title><title level="j" type="abbrev">Med Microbiol Immunol</title><idno type="pISSN">0300-8584</idno><idno type="eISSN">1432-1831</idno><idno type="journal-ID">true</idno><idno type="issue-article-count">9</idno><idno type="volume-issue-count">4</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="2007-12-01"></date><biblScope unit="volume">196</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="213">213</biblScope><biblScope unit="page" to="225">225</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007-05-03</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Among emerging and re-emerging infectious diseases, influenza constitutes one of the major threats to mankind. In this review series epidemiologic, virologic and pathologic concerns raised by infections of humans with avian influenza virus A/H5N1 are discussed. This fourth part focuses on vaccine development. Several phase I clinical studies with vaccines against H5 viruses have demonstrated limited efficacy compared to seasonal influenza vaccines. To induce protective immunity two immunisations with increased amounts of H5N1 vaccine were required. Novel vaccination strategies that are egg- and adjuvant-independent, broadly cross-reactive and long-lasting are highly desirable.</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>Biomedicine</head><item><term>Immunology</term></item><item><term>Medical Microbiology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-05-03">Created</change><change when="2007-12-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-N26CZ5CC-J/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus springer-journals not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Springer-Verlag</PublisherName><PublisherLocation>Berlin/Heidelberg</PublisherLocation></PublisherInfo><Journal OutputMedium="All"><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>430</JournalID><JournalPrintISSN>0300-8584</JournalPrintISSN><JournalElectronicISSN>1432-1831</JournalElectronicISSN><JournalTitle>Medical Microbiology and Immunology</JournalTitle><JournalAbbreviatedTitle>Med Microbiol Immunol</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Biomedicine</JournalSubject><JournalSubject Type="Secondary">Immunology</JournalSubject><JournalSubject Type="Secondary">Medical Microbiology </JournalSubject></JournalSubjectGroup></JournalInfo><Volume OutputMedium="All"><VolumeInfo TocLevels="0" VolumeType="Regular"><VolumeIDStart>196</VolumeIDStart><VolumeIDEnd>196</VolumeIDEnd><VolumeIssueCount>4</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular" OutputMedium="All"><IssueInfo TocLevels="0"><IssueIDStart>4</IssueIDStart><IssueIDEnd>4</IssueIDEnd><IssueArticleCount>9</IssueArticleCount><IssueHistory><OnlineDate><Year>2007</Year><Month>8</Month><Day>13</Day></OnlineDate><PrintDate><Year>2007</Year><Month>8</Month><Day>13</Day></PrintDate><CoverDate><Year>2007</Year><Month>12</Month></CoverDate></IssueHistory><IssueCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>2007</CopyrightYear></IssueCopyright></IssueInfo><Article ID="s00430-007-0052-3" OutputMedium="All"><ArticleInfo ArticleType="ReviewPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0"><ArticleID>52</ArticleID><ArticleDOI>10.1007/s00430-007-0052-3</ArticleDOI><ArticleSequenceNumber>4</ArticleSequenceNumber><ArticleTitle Language="En">The threat of avian influenza A (H5N1). Part IV: development of vaccines</ArticleTitle><ArticleCategory>Review</ArticleCategory><ArticleFirstPage>213</ArticleFirstPage><ArticleLastPage>225</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2007</Year><Month>5</Month><Day>10</Day></RegistrationDate><Received><Year>2007</Year><Month>5</Month><Day>3</Day></Received><OnlineDate><Year>2007</Year><Month>6</Month><Day>1</Day></OnlineDate></ArticleHistory><ArticleCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>2007</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Jindrich</GivenName><FamilyName>Cinatl jr</FamilyName></AuthorName><Contact><Phone>+49-69-63016409</Phone><Fax>+49-69-63014302</Fax><Email>cinatl@em.uni-frankfurt.de</Email></Contact></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Martin</GivenName><FamilyName>Michaelis</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Hans</GivenName><GivenName>W.</GivenName><FamilyName>Doerr</FamilyName></AuthorName><Contact><Phone>+49-69-63015219</Phone><Fax>+49-69-63016477</Fax><Email>h.w.doerr@em.uni-frankfurt.de</Email></Contact></Author><Affiliation ID="Aff1"><OrgDivision>Institute for Medical Virology</OrgDivision><OrgName>Hospital of the Johann Wolfgang Goethe University</OrgName><OrgAddress><Street>Paul-Ehrlich-Str. 40</Street><Postcode>60596</Postcode><City>Frankfurt/M</City><Country Code="DE">Germany</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En"><Heading>Abstract</Heading><Para>Among emerging and re-emerging infectious diseases, influenza constitutes one of the major threats to mankind. In this review series epidemiologic, virologic and pathologic concerns raised by infections of humans with avian influenza virus A/H5N1 are discussed. This fourth part focuses on vaccine development. Several phase I clinical studies with vaccines against H5 viruses have demonstrated limited efficacy compared to seasonal influenza vaccines. To induce protective immunity two immunisations with increased amounts of H5N1 vaccine were required. Novel vaccination strategies that are egg- and adjuvant-independent, broadly cross-reactive and long-lasting are highly desirable.</Para></Abstract></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>The threat of avian influenza A (H5N1). Part IV: development of vaccines</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>The threat of avian influenza A (H5N1). Part IV: development of vaccines</title></titleInfo><name type="personal" displayLabel="corresp"><namePart type="given">Jindrich</namePart><namePart type="family">Cinatl jr</namePart><affiliation>Institute for Medical Virology, Hospital of the Johann Wolfgang Goethe University, Paul-Ehrlich-Str. 40, 60596, Frankfurt/M, Germany</affiliation><affiliation>E-mail: cinatl@em.uni-frankfurt.de</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Martin</namePart><namePart type="family">Michaelis</namePart><affiliation>Institute for Medical Virology, Hospital of the Johann Wolfgang Goethe University, Paul-Ehrlich-Str. 40, 60596, Frankfurt/M, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal" displayLabel="corresp"><namePart type="given">Hans</namePart><namePart type="given">W.</namePart><namePart type="family">Doerr</namePart><affiliation>Institute for Medical Virology, Hospital of the Johann Wolfgang Goethe University, Paul-Ehrlich-Str. 40, 60596, Frankfurt/M, Germany</affiliation><affiliation>E-mail: h.w.doerr@em.uni-frankfurt.de</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="ReviewPaper" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>Springer-Verlag</publisher><place><placeTerm type="text">Berlin/Heidelberg</placeTerm></place><dateCreated encoding="w3cdtf">2007-05-03</dateCreated><dateIssued encoding="w3cdtf">2007-12-01</dateIssued><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract lang="en">Abstract: Among emerging and re-emerging infectious diseases, influenza constitutes one of the major threats to mankind. In this review series epidemiologic, virologic and pathologic concerns raised by infections of humans with avian influenza virus A/H5N1 are discussed. This fourth part focuses on vaccine development. Several phase I clinical studies with vaccines against H5 viruses have demonstrated limited efficacy compared to seasonal influenza vaccines. To induce protective immunity two immunisations with increased amounts of H5N1 vaccine were required. Novel vaccination strategies that are egg- and adjuvant-independent, broadly cross-reactive and long-lasting are highly desirable.</abstract><note>Review</note><relatedItem type="host"><titleInfo><title>Medical Microbiology and Immunology</title></titleInfo><titleInfo type="abbreviated"><title>Med Microbiol Immunol</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>Springer</publisher><dateIssued encoding="w3cdtf">2007-08-13</dateIssued><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><subject><genre>Biomedicine</genre><topic>Immunology</topic><topic>Medical Microbiology</topic></subject><identifier type="ISSN">0300-8584</identifier><identifier type="eISSN">1432-1831</identifier><identifier type="JournalID">430</identifier><identifier type="IssueArticleCount">9</identifier><identifier type="VolumeIssueCount">4</identifier><part><date>2007</date><detail type="volume"><number>196</number><caption>vol.</caption></detail><detail type="issue"><number>4</number><caption>no.</caption></detail><extent unit="pages"><start>213</start><end>225</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 2007</recordOrigin></recordInfo></relatedItem><identifier type="istex">6A375247B03FB33CBC942FE9C9E5976035C9F2EF</identifier><identifier type="ark">ark:/67375/VQC-N26CZ5CC-J</identifier><identifier type="DOI">10.1007/s00430-007-0052-3</identifier><identifier type="ArticleID">52</identifier><identifier type="ArticleID">s00430-007-0052-3</identifier><accessCondition type="use and reproduction" contentType="copyright">Springer-Verlag, 2007</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</recordContentSource><recordOrigin>Springer-Verlag, 2007</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-N26CZ5CC-J/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000251 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000251 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:6A375247B03FB33CBC942FE9C9E5976035C9F2EF
|texte= The threat of avian influenza A (H5N1). Part IV: development of vaccines
}}
| This area was generated with Dilib version V0.6.33. |  |